AEE-788 - CAS 497839-62-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
AEE-788
Catalog Number:
497839-62-0
Synonyms:
AEE788; AEE 788.
CAS Number:
497839-62-0
Description:
AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis.
COA:
Inquire
MSDS:
Inquire
Targets:
EGFR
Current Developer:
Novartis International AG。
Chemical Structure
CAS 497839-62-0 AEE-788

Related EGFR Products


CAS 153436-54-5 PD-153035

PD-153035
(CAS: 153436-54-5)

PD153035 is a ATP-competitive EGFR inhibitor with an IC50 and Ki of 25 and 6 pM. PD153035 effectively blocks the enhancement of mitogenesis, induction of early ...

CAS 845272-21-1 Varlitinib

Varlitinib
(CAS: 845272-21-1)

Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. V...

CAS 118409-57-7 AG-18

AG-18
(CAS: 118409-57-7)

AG 18 (10 μM) inhibits EGF-induced proliferation of GH3 cells.

CAS 184475-55-6 Gefitinib hydrochloride

Gefitinib hydrochloride
(CAS: 184475-55-6)

Gefitinib Hcl(ZD-1839 Hcl) is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.

PF-06459988
(CAS: 1428774-45-1)

PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including th...

Naquotinib
(CAS: 1448232-80-1)

Naquotinib is a irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activitywith ...

CAS 366017-09-6 Mubritinib

Mubritinib
(CAS: 366017-09-6)

Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinic...

CAS 1421373-66-1 AZD-9291 mesylate

AZD-9291 mesylate
(CAS: 1421373-66-1)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

CAS 248594-19-6 Erlotinib mesylate

Erlotinib mesylate
(CAS: 248594-19-6)

Erlotinib is an EGFR inhibitor. The drug follows Iressa (gefitinib), which was the first drug of this type. Erlotinib specifically targets the epidermal growth ...

CGP-59326
(CAS: 173458-56-5)

CGP-59326, a pyrrolopyrimidine derivative, has been found to be an EGFR antagonist and could used in antineoplastic studies.

CAS 388082-77-7 Lapatinib Ditosylate

Lapatinib Ditosylate
(CAS: 388082-77-7)

Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth ...

CAS 451492-95-8 MP-412

MP-412
(CAS: 451492-95-8)

MP-412 (AV-412) is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to an...

CAS 1421373-62-7 Mutant EGFR inhibitor

Mutant EGFR inhibitor
(CAS: 1421373-62-7)

CAS 257933-82-7 Pelitinib

Pelitinib
(CAS: 257933-82-7)

Pelitinib is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal gr...

CAS 194423-06-8 CL-387785

CL-387785
(CAS: 194423-06-8)

CL-387785, also known as EKI-785, is an irreversible inhibitor of EGF-receptor (EGFR) kinase activity in vivo (IC50 = 250-490 pM). CL-387785 covalently bound t...

CAS 1214265-57-2 WZ-8040

WZ-8040
(CAS: 1214265-57-2)

WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor with potential anticancer activity. WZ8040 is about 30-fold more potent against EGFR T790M, ...

CO-1686 hydrobromide
(CAS: 1446700-26-0)

CO-1686 hydrobromide is the hydrobromide salt form of CO-1686. CO-1686, also called as Rociletinib, is an oral tyrosine kinase inhibitor that irreversibly and s...

Anlotinib
(CAS: 1058156-90-3)

Anlotibib is a multi-targetes kinase inhibitor of receptor tyrosine and could effectively resist the formation of new angiogenesis and is under Phase III trail ...

CAS 1421372-66-8 AZD9291DA HCl salt

AZD9291DA HCl salt
(CAS: 1421372-66-8)

AZD9291-DA is a des acryl analogue of AZD9291, which is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients ...

CAS 171179-06-9 PD158780

PD158780
(CAS: 171179-06-9)

PD158780 is a potent, cell-permeable, reversible ATP-competitive inhibitor of EGFR tyrosine kinase activity with IC50 values of 0.008, 49 and 52 nM for EGFR, Er...